Researchers have developed a vaccine that provides broad cross-reactive immunity against the H9N2 influenza virus. The vaccine, which utilizes epitope-optimized influenza hemagglutinin nanoparticles, is part of a broader effort to create vaccines that offer protection against multiple influenza viruses. Studies suggest that such vaccines can confer broad protection and stimulate both humoral and cellular immune responses.